Skip to main content
EC

EGB Capital

Opeator is a fermentation technology company that utilizes an anaerobic process to enhance the efficiency and scalability of industrial fermentation. By enabling extended fermentation runs and employing low-cost bioreactors, the company improves process robustness and reduces operational costs for various industries.

Berkeley, United StatesFounded 2018110+ followers
Updated 3 months ago

Funding

$2.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

Funding rounds are not available yet.

Founders

Founder details are not available yet.

Product

Problem

Traditional industrial fermentation processes rely on oxygen, requiring complex and costly systems for aeration and mixing in bioreactors. These systems limit scalability, increase capital expenditures, and complicate process design.

Solution

Izote Biosciences offers a fermentation technology that utilizes an alternative molecule to oxygen, enabling anaerobic biomanufacturing. This approach simplifies fermentation design, reduces the need for traditional aeration methods, and allows for extended fermentation runs. By eliminating the requirement for air compressors, blowers, and agitators, Izote's technology reduces operational and capital expenses while improving process robustness. The system facilitates predictable scaling of performance and enables the use of low-cost bioreactors and feedstocks.

Target Audience

The primary customers are companies in the fragrance, pharmaceutical, and specialty chemical industries seeking to manufacture small molecules and proteins more efficiently and cost-effectively.

Features

  • Anaerobic fermentation process using a highly soluble alternative molecule to oxygen
  • Simplified bioreactor design, eliminating the need for complex aeration systems
  • Enables extended fermentation runs for increased productivity
  • Highly predictable scaling of performance from lab to industrial scale
  • Compatible with low-cost bioreactors and feedstocks
  • Reduces operational expenses by up to 50%
  • Reduces energy consumption by up to 70%
  • Reduces capital expenditures by up to 90%
This profile is AI-generated and may contain inaccuracies.